Bank of America spin-off Ridgemont Equity Partners’ latest investment is a majority stake in Gallus Biopharmaceuticals LLC, a St. Louis-based biologics contract manufacturer.
Enterprise Bank & Trust provided senior financing for the deal.
The investment from Ridgemont facilitated Gallus’ acquisition of a biologics manufacturing plant from Centocor Biologics LLC. The plant currently makes Remicade, a drug treatment for Crohn’s Disease and rheumatoid arthritis, and Stelara, which treats plaque psoriasis, a skin disease.
